跳到主要导航 跳到搜索 跳到主要内容

Corrigendum to ‘Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer’ [EBioMedicine 31 (2018) 276–286](S2352396418301580)(10.1016/j.ebiom.2018.05.003)

  • Tao Zhang*
  • , Jingjie Li
  • , Xiaojun Ma
  • , Yang Yang
  • , Wei Sun
  • , Wangrui Jin
  • , Lei Wang
  • , Yuan He
  • , Feifei Yang
  • , Zhengfang Yi
  • , Yingqi Hua
  • , Mingyao Liu
  • , Yihua Chen
  • , Zhengdong Cai
  • *此作品的通讯作者
  • Shanghai Jiao Tong University
  • Shanghai Bone Tumor Institution
  • East China Normal University
  • University of Jinan
  • Texas A&M University

科研成果: 期刊稿件评论/辩论

摘要

The published version of this article contained an error in Fig. 2c and f, the corrected Fig. 2 is included below, the authors declare that the corrections do not change the results or conclusions of this paper and apologize for any inconvenience this may have caused.

源语言英语
文章编号102629
期刊eBioMedicine
52
DOI
出版状态已出版 - 2月 2020

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

指纹

探究 'Corrigendum to ‘Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer’ [EBioMedicine 31 (2018) 276–286](S2352396418301580)(10.1016/j.ebiom.2018.05.003)' 的科研主题。它们共同构成独一无二的指纹。

引用此